1 pixel 1 empty pixel
This is a decorative photo newsbg

Aurora-Based Prollenium Medical Technologies Inc. Announces U.S. FDA Approval for its Cross-Linked Hyaluronic Acid Dermal Filler

ProlleniumAURORA, ON, Aug. 17, 2017 /CNW/ - Prollenium Medical Technologies Inc., a leading medical device manufacturer, announced today its United States (U.S.) Food and Drug Administration (FDA) approval for its cross-linked hyaluronic acid dermal filler. 
Categorized in: Business, Life Sciences & Health Technology Posted on: Last updated on: Written by:

ProlleniumAURORA, ON, Aug. 17, 2017 /CNW/ – Prollenium Medical Technologies Inc., a leading medical device manufacturer, announced today its United States (U.S.) Food and Drug Administration (FDA) approval for its cross-linked hyaluronic acid dermal filler. Ario Khoshbin, Founder and CEO, stated “This is definitely one of our proudest moments as an organization. FDA approval is a culmination of efforts from every single member of our team.

Full article: www.newswire.ca